Neurocrine to buy Soleno Therapeutics for $2.9 billion

Chronological Source Flow
Back

AI Fusion Summary

Neurocrine announced a $2.9 billion acquisition of Soleno Therapeutics, paying $53 per share—a 34% premium. Soleno’s Vykat, approved March 2025, treats hyperphagia in Prader‑Willi syndrome, the only approved therapy for this condition.
#NEUROCRINE #SOLENO #VYKAT #PRADER_WILLI #MERGER #PHARMACEUTICAL #US_MARKET
06/04 14:12 yahoo.com
3 Πηγές

Neurocrine to buy Soleno Therapeutics for $2.9 billion

POLITICS
06/04 14:12 investing.com

Neurocrine to buy Soleno Therapeutics for $2.9 billion

Neurocrine TherapeuticsSoleno Therapeuticsacquisition$2.9 billionneurodegenerative diseasesrare disease therapies
06/04 14:58 statnews.com

STAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal

POLITICSBIOTECHNOLOGYSTAT+BIOTECHDRUG DEVELOPMENTRARE DISEASE
Comments
Loading...
0